Charles M. Laymon

Dr. Charles M. Laymon


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in NeuroImage
Verified
Journal Article
Open access
MZMatthew D. Zammit
Matthew D. Zammit
DTDana L. Tudorascu
Dana L. Tudorascu
CLCharles M. Laymon
Charles M. Laymon
SHSigan L. Hartley
Sigan L. Hartley
SZShahid Zaman
Shahid Zaman
BCBradley Christian
Bradley Christian
Adults with Down syndrome (DS) are predisposed to Alzheimer's disease (AD) and reveal early amyloid beta (Aβ) pathology in the brain. Positron emission tomography (PET) provides an in vivo measure of Aβ throughout the AD continuum. Due to the high prevalence of AD in DS, there is need for longitudinal imaging studies of Aβ to better characterize the natural history of Aβ accumulation, which will aid in the staging of this population for clinical trials aimed at AD treatment and prevention. Adults with DS (N = 79; Mean age (SD) = 42.7 (7.28) years) underwent longitudinal [C-11]Pittsburgh compound B (PiB) PET. Global Aβ burden was quantified using the amyloid load metric (AβL). Modeled PiB images were generated from the longitudinal AβL data to visualize which regions are most susceptible to Aβ accumulation in DS. AβL change was evaluated across Aβ(-), Aβ-converter, and Aβ(+) groups to assess longitudinal Aβ trajectories during different stages of AD-pathology progression. AβL change values were used to identify Aβ-accumulators within the Aβ(-) group prior to reaching the Aβ(+) threshold (previously reported as 20 AβL) which would have resulted in an Aβ-converter classification. With knowledge of trajectories of Aβ(-) accumulators, a new cutoff of Aβ(+) was derived to better identify subthreshold Aβ accumulation in DS. Estimated sample sizes necessary to detect a 25% reduction in annual Aβ change with 80% power (alpha 0.01) were determined for different groups of Aβ-status. Modeled PiB images revealed the striatum, parietal cortex and precuneus as the regions with earliest detected Aβ accumulation in DS. The Aβ(-) group had a mean AβL change of 0.38 (0.58) AβL/year, while the Aβ-converter and Aβ(+) groups had change of 2.26 (0.66) and 3.16 (1.34) AβL/year, respectively. Within the Aβ(-) group, Aβ-accumulators showed no significant difference in AβL change values when compared to Aβ-converter and Aβ(+) groups. An Aβ(+) cutoff for subthreshold Aβ accumulation was derived as 13.3 AβL. The estimated sample size necessary to detect a 25% reduction in Aβ was 79 for Aβ(-) accumulators and 59 for the Aβ-converter/Aβ(+) group in DS. Longitudinal AβL changes were capable of distinguishing Aβ accumulators from non-accumulators in DS. Longitudinal imaging allowed for identification of subthreshold Aβ accumulation in DS during the earliest stages of AD-pathology progression. Detection of active Aβ deposition evidenced by subthreshold accumulation with longitudinal imaging can identify DS individuals at risk for AD development at an earlier stage.

18 July 2019 in Molecular Imaging and Biology
Verified
Journal Article
Open access
PDF file
XLXiaoxi Ling
Xiaoxi Ling
JLJoseph D. Latoche
Joseph D. Latoche
CCCindy J. Choy
Cindy J. Choy
BKBrenda F. Kurland
Brenda F. Kurland
CLCharles M. Laymon
Charles M. Laymon
CACarolyn J. Anderson
Carolyn J. Anderson
Purpose Prostate-specific membrane antigen (PSMA) continues to be the hallmark biomarker for prostate cancer as it is expressed on nearly all prostatic tumors. In addition, increased PSMA expression correlates with castration resistance and progression to the metastatic stage of the disease. Recently, we combined both an albumin-binding motif and an irreversible PSMA inhibitor to develop the novel PSMA-targeted radiotherapeutic agent, CTT1403. This molecule was novel in the field of PSMA-targeted agents as its key motifs resulted in extended blood circulation time and tumor uptake, rapid and extensive internalization into PSMA+ cells, and promising therapeutic efficacy. The objective of this study was to perform IND-enabling translational studies on CTT1403 in rodent models. Procedures A dose optimization study was performed in PC3-PIP (PSMA+) tumor-bearing mice. Treatment groups were randomly selected to receive one to three 14-MBq injections of CTT1403. Control groups included (1) saline, (2) non-radioactive [175Lu]CTT1403, or (3) two injections of 14 MBq CTT1751, a Lu-177-labeled non-targeted albumin-binding moiety. Tumor growth was monitored up to 120 days. Small-animal single photon emission tomography/X-ray computed tomography imaging was performed with CTT1403 and CTT1751 in PC3-PIP tumor-bearing mice to visualize infiltration of the Lu-177-labeled agent into the tumor. In preparation for a first-in-human study, human absorbed doses were estimated based on rat biodistribution out to 5 weeks to determine a safe CTT1403 therapy dose in humans. Results Two to 3 injections of 14 MBq CTT1403 yielded significant tumor growth inhibition and increased survival compared with all control groups and mice receiving 1 injection of 14 MBq CTT1403. Five of 12 mice receiving 2 or 3 injections of CTT1403 survived to the 120-day post-treatment study endpoint. Dosimetry identified the kidneys as the dose-limiting organ, with an equivalent dose of 5.18 mSv/MBq, resulting in a planned maximum dose of 4.4 GBq for phase 1 clinical trials. Conclusions The preclinical efficacy and dosimetry of CTT1403 suggest that this agent has significant potential to be safe and effective in humans.

10 December 2016 in Medical Physics
Verified
Journal Article
Open access
PDF file
RBReinhard R Beichel
Reinhard R Beichel
BSBrian J. Smith
Brian J. Smith
CBChristian Bauer
Christian Bauer
EUEthan J. Ulrich
Ethan J. Ulrich
PAPayam Ahmadvand
Payam Ahmadvand
JBJohn Buatti
John Buatti
Purpose: Radiomics utilizes a large number of image‐derived features for quantifying tumor characteristics that can in turn be correlated with response and prognosis. Unfortunately, extraction and analysis of such image‐based features is subject to measurement variability and bias. The challenge for radiomics is particularly acute in Positron Emission Tomography (PET) where limited resolution, a high noise component related to the limited stochastic nature of the raw data, and the wide variety of reconstruction options confound quantitative feature metrics. Extracted feature quality is also affected by tumor segmentation methods used to define regions over which to calculate features, making it challenging to produce consistent radiomics analysis results across multiple institutions that use different segmentation algorithms in their PET image analysis. Understanding each element contributing to these inconsistencies in quantitative image feature and metric generation is paramount for ultimate utilization of these methods in multi‐institutional trials and clinical oncology decision making.Methods: To assess segmentation quality and consistency at the multi‐institutional level, we conducted a study of seven institutional members of the National Cancer Institute Quantitative Imaging Network. For the study, members were asked to segment a common set of phantom PET scans acquired over a range of imaging conditions as well as a second set of head and neck cancer (HNC) PET scans. Segmentations were generated at each institution using their preferred approach. In addition, participants were asked to repeat segmentations with a time interval between initial and repeat segmentation. This procedure resulted in overall 806 phantom insert and 641 lesion segmentations. Subsequently, the volume was computed from the segmentations and compared to the corresponding reference volume by means of statistical analysis.Results: On the two test sets (phantom and HNC PET scans), the performance of the seven segmentation approaches was as follows. On the phantom test set, the mean relative volume errors ranged from 29.9 to 87.8% of the ground truth reference volumes, and the repeat difference for each institution ranged between −36.4 to 39.9%. On the HNC test set, the mean relative volume error ranged between −50.5 to 701.5%, and the repeat difference for each institution ranged between −37.7 to 31.5%. In addition, performance measures per phantom insert/lesion size categories are given in the paper. On phantom data, regression analysis resulted in coefficient of variation (CV) components of 42.5% for scanners, 26.8% for institutional approaches, 21.1% for repeated segmentations, 14.3% for relative contrasts, 5.3% for count statistics (acquisition times), and 0.0% for repeated scans. Analysis showed that the CV components for approaches and repeated segmentations were significantly larger on the HNC test set with increases by 112.7% and 102.4%, respectively.Conclusion: Analysis results underline the importance of PET scanner reconstruction harmonization and imaging protocol standardization for quantification of lesion volumes. In addition, to enable a distributed multi‐site analysis of FDG PET images, harmonization of analysis approaches and operator training in combination with highly automated segmentation methods seems to be advisable. Future work will focus on quantifying the impact of segmentation variation on radiomics system performance.

1 November 2012 in Magnetic Resonance Imaging
Verified
Journal Article
Closed access
MLMia A. Levy
Mia A. Levy
JFJohn B. Freymann
John B. Freymann
JKJustin S. Kirby
Justin S. Kirby
AFAndrey Fedorov
Andrey Fedorov
FFFiona M. Fennessy
Fiona M. Fennessy
DRDaniel Rubin
Daniel Rubin

1 May 2013 in Clinical Nuclear Medicine
Verified
Journal Article
Open access
MOMatthew J. Oborski
Matthew J. Oborski
CLCharles M. Laymon
Charles M. Laymon
FLFrank Lieberman
Frank Lieberman
James Michael MountzJames Michael Mountz
James Michael Mountz
We report a case in which 18F-FDG PET was able to discriminate pseudoprogression from progression observed on contrast-enhanced (CE) MRI (CE-MRI). A 56-year-old male patient with anaplastic oligodendroglioma demonstrated markedly increased tumor enhancement on CE-MRI 1 month after completing radiation therapy (RT), suggesting radiological progression. However, the patient was clinically improved and therefore received an early-therapy response assessment PET to assess for pseudoprogression. PET showed low tumor uptake indicating stable disease. Follow-up CE-MRI at 3 and 4 months post-RT confirmed stable disease. This case emphasizes the value of 18F-FDG PET when pseudoprogression is clinically suspected.

16 April 2009 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
CLCharles M. Laymon
Charles M. Laymon
NMN. Scott Mason
N. Scott Mason
WFW. Gordon Frankle
W. Gordon Frankle
JCJonathan P. Carney
Jonathan P. Carney
BLBrian J. Lopresti
Brian J. Lopresti
RNRajesh Narendran
Rajesh Narendran
We measured the whole-body distribution of intravenously injected 11C-N-propylnorapomorphine (11C-NPA), a dopamine agonist PET tracer, in human subjects and determined the resulting absorbed radiation doses. Methods: Six subjects (3 women, 3 men) were injected with 11C-NPA (nominal dose, 370 MBq). A total of 9 consecutive whole-body PET scans were obtained for each subject. In addition, time–activity curves for 12 organs were determined, and residence times were computed for each subject. Dosimetry was determined for the various body organs and the whole body. Results: The average NPA whole-body radiation dose was 3.17 × 10−3 mSv per MBq of injected 11C-NPA. The organ receiving the highest dose was the gallbladder wall, with an average of 2.81 × 10−2 mSv·MBq−1. Conclusion: On the basis of averaged dosimetry results, an administration of less than 1,780 MBq (<48 mCi) of 11C-NPA yields an organ dose of under 50 mSv (5 rem) to all organs.